Physician profile
Daniel J Cunningham
NPI 1184156911
$8,258.24
in general payments reported to CMS, 2019-2025
7 companies · $489 in 2025
The $489 reported for 2025 was less than what a typical Orthopaedic Trauma provider received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,800 · 2023: $2,713 · 2024: $257 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $909 · Travel and Lodging: $49.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $909.09 |
| Travel and Lodging | $49.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Southtech Orthopedics | $4,800.00 | 2021 | |
| Smith+Nephew, INC. | $2,883.35 | 2023-2025 | Evos |
| Depuy Synthes Sales INC. | $395.41 | 2024-2025 | Na |
| Stryker Corporation | $82.71 | 2023-2024 | Gamma, T2, Aequalis Perform |
| Solventum Corporation | $54.21 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Sanara Medtech INC. | $23.18 | 2025 | Celleraterx |
| Pacira Pharmaceuticals Incorporated | $19.38 | 2023 | Iovera, Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.